Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment

Patients with idiopathic pulmonary fibrosis (IPF) demonstrate a range of lung function impairment. However, the efficacy of antifibrotics compared with placebo has not been assessed in patients with more advanced disease. This post-hoc analysis investigated the efficacy and safety of pirfenidone versus placebo in patients with IPF and more advanced lung function impairment, defined as percent predicted forced vital capacity (%FVC)  

Source: Respiratory Medicine - April 23, 2019 Category: Respiratory Medicine Authors: Steven D. Nathan, Ulrich Costabel, Carlo Albera, J ürgen Behr, Wim A. Wuyts, Klaus-Uwe Kirchgaessler, John L. Stauffer, Elizabeth Morgenthien, Willis Chou, Susan L. Limb, Paul W. Noble Source Type: research